                         SEQUENCE LISTING

<110>  AEROVANCE, INC.
       LALOR, Cecily B.
       TEPPER, Jeffrey S.
       FROLAND, Wayne A.
 
<120>  PHARMACEUTICAL POLYPEPTIDE DRY POWDER AEROSOL 
       FORMULATION AND METHOD OF PREPARATION

<130>  AERO1250-1WO

<150>  US 60/959,267
<151>  2007-07-11

<160>  4     

<170>  PatentIn version 3.4

<210>  1
<211>  129
<212>  PRT
<213>  Homo sapiens

<400>  1

His Lys Cys Asp Ile Thr Leu Gln Glu Ile Ile Lys Thr Leu Asn Ser 
1               5                   10                  15      


Leu Thr Glu Gln Lys Thr Leu Cys Thr Glu Leu Thr Val Thr Asp Ile 
            20                  25                  30          


Phe Ala Ala Ser Lys Asn Thr Thr Glu Lys Glu Thr Phe Cys Arg Ala 
        35                  40                  45              


Ala Thr Val Leu Arg Gln Phe Tyr Ser His His Glu Lys Asp Thr Arg 
    50                  55                  60                  


Cys Leu Gly Ala Thr Ala Gln Gln Phe His Arg His Lys Gln Leu Ile 
65                  70                  75                  80  


Arg Phe Leu Lys Arg Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly Leu 
                85                  90                  95      


Asn Ser Cys Pro Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn Phe 
            100                 105                 110         


Leu Glu Arg Leu Lys Thr Ile Met Arg Glu Lys Tyr Ser Lys Cys Ser 
        115                 120                 125             


Ser 
    


<210>  2
<211>  387
<212>  DNA
<213>  Homo sapiens

<400>  2
cacaagtgcg atatcacctt acaggagatc atcaaaactt tgaacagcct cacagagcag     60

aagactctgt gcaccgagtt gaccgtaaca gacatctttg ctgcctccaa gaacacaact    120

gagaaggaaa ccttctgcag ggctgcgact gtgctccggc agttctacag ccaccatgag    180

aaggacactc gctgcctggg tgcgactgca cagcagttcc acaggcacaa gcagctgatc    240

cgattcctga aacggctcga caggaacctc tggggcctgg cgggcttgaa ttcctgtcct    300

gtgaaggaag ccaaccagag tacgttggaa aacttcttgg aaaggctaaa gacgatcatg    360

agagagaaat attcaaagtg ttcgagc                                        387


<210>  3
<211>  130
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  3

Met His Lys Cys Asp Ile Thr Leu Gln Glu Ile Ile Lys Thr Leu Asn 
1               5                   10                  15      


Ser Leu Thr Glu Gln Lys Thr Leu Cys Thr Glu Leu Thr Val Thr Asp 
            20                  25                  30          


Ile Phe Ala Ala Ser Lys Asn Thr Thr Glu Lys Glu Thr Phe Cys Arg 
        35                  40                  45              


Ala Ala Thr Val Leu Arg Gln Phe Tyr Ser His His Glu Lys Asp Thr 
    50                  55                  60                  


Arg Cys Leu Gly Ala Thr Ala Gln Gln Phe His Arg His Lys Gln Leu 
65                  70                  75                  80  


Ile Arg Phe Leu Lys Arg Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly 
                85                  90                  95      


Leu Asn Ser Cys Pro Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn 
            100                 105                 110         


Phe Leu Glu Arg Leu Lys Thr Ile Met Asp Glu Lys Asp Ser Lys Cys 
        115                 120                 125             


Ser Ser 
    130 


<210>  4
<211>  396
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  4
atgcacaaat gcgatatcac cctgcaggaa atcatcaaaa ccctgaattc tctgaccgaa     60

cagaaaaccc tgtgcaccga actgaccgtt accgacatct tcgctgcttc gaaaaacacc    120

accgaaaaag aaaccttctg ccgtgctgct accgttctgc gtcagttcta ctctcaccac    180

gaaaaagaca cccgttgcct gggtgctacc gctcagcagt tccaccgtca caaacagctg    240

atccgtttcc tgaaacgtct ggaccgtaac ctgtggggtc tggctggtct gaacagctgc    300

ccggttaaag aagctaacca gtctaccctg gaaaacttcc tggaacgtct gaaaaccatc    360

atggacgaaa aagactctaa atgctcttct taataa                              396


